open access

Vol 12, No 1 (2021)
Case report
Get Citation

Ponatinib in treatment of chronic myeloid leukemia with T315I mutation

Klaudia Cieśluk1, Jarosław Piszcz1
DOI: 10.5603/HCP.2021.0006
·
Hematology in Clinical Practice 2021;12(1):33-35.
Affiliations
  1. Department of Haematology, Medical University of Bialystok

open access

Vol 12, No 1 (2021)
CASE REPORTS

Abstract

Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation t(9;22)(q34;q11) which causes the formation of the Philadelphia chromosome (Ph). Therapeutic progress made in the last two decades and new-generation tyrosine kinase inhibitors (TKIs) introduction, signifi cantly increased patients’ prognosis. We present a case study of a Ph-positive CML patient with a point BCR/ABL1 mutation T315I treated with ponatinib.

Abstract

Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation t(9;22)(q34;q11) which causes the formation of the Philadelphia chromosome (Ph). Therapeutic progress made in the last two decades and new-generation tyrosine kinase inhibitors (TKIs) introduction, signifi cantly increased patients’ prognosis. We present a case study of a Ph-positive CML patient with a point BCR/ABL1 mutation T315I treated with ponatinib.

Get Citation

Keywords

chronic myeloid leukemia, CML, Philadelphia chromosome, T315I mutation, TKIs, ponatinib

About this article
Title

Ponatinib in treatment of chronic myeloid leukemia with T315I mutation

Journal

Hematology in Clinical Practice

Issue

Vol 12, No 1 (2021)

Article type

Case report

Pages

33-35

DOI

10.5603/HCP.2021.0006

Bibliographic record

Hematology in Clinical Practice 2021;12(1):33-35.

Keywords

chronic myeloid leukemia
CML
Philadelphia chromosome
T315I mutation
TKIs
ponatinib

Authors

Klaudia Cieśluk
Jarosław Piszcz

References (5)
  1. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. The Lancet. 2007; 370(9584): 342–350.
  2. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966–984.
  3. Harrington P, Kizilors A, de Lavallade H. The role of early molecular response in the management of chronic phase CML. Curr Hematol Malig Rep. 2017; 12(2): 79–84.
  4. Molica M, Scalzulli E, Colafigli G, et al. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther Adv Hematol. 2019; 10: 2040620719826444.
  5. https://www.ema.europa.eu/en/documents/product.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.